We are making all efforts to reimburse ¡®Vyndamax¡¯
By Eo, Yun-Ho | translator Alice Kang
22.04.20 16:21:53
°¡³ª´Ù¶ó
0
¡°Have continuously worked to persuade the head office¡¦ will focus on passing the Drug Reimbursement Standard Subcommittee¡±
¡°Need to address areas unattended by the reimbursement listing system¡¦ rare disease drugs have difficulty demonstrating cost-effectiveness¡±
¡ã±èÈñÁ¤ Àü¹«
Rare disease patients suffer more due to the 'rarity' of their condition. Due to the small number of affected patients, even drugs that are already available cannot be easily listed for reimbursement due to difficulty in demonstrating cost-effectiveness or predicting their fiscal impact on the NHI budget. Rare diseases are diseases that affect fewer than 20,000 people or those for which the number of affected patients cannot be estimated due to difficulties in diagnosis. As rare diseases are difficult to diagnose and treat and have a significant impact on the life expectancy of the patients, it is imperative to ensure patient access to the treatments. However, due to the small number of affected pati
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)